42,021 Shares in DexCom, Inc. (NASDAQ:DXCM) Bought by Watts Gwilliam & Co. LLC

Watts Gwilliam & Co. LLC bought a new position in shares of DexCom, Inc. (NASDAQ:DXCM) during the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The fund bought 42,021 shares of the medical device company’s stock, valued at approximately $3,334,000.

Several other large investors also recently modified their holdings of DXCM. Versant Capital Management Inc bought a new position in shares of DexCom during the 4th quarter valued at about $25,000. Riverview Trust Co lifted its stake in DexCom by 100.4% in the third quarter. Riverview Trust Co now owns 463 shares of the medical device company’s stock valued at $31,000 after buying an additional 232 shares in the last quarter. RPg Family Wealth Advisory LLC bought a new position in DexCom in the third quarter valued at approximately $57,000. Covestor Ltd boosted its holdings in shares of DexCom by 53.7% in the third quarter. Covestor Ltd now owns 959 shares of the medical device company’s stock valued at $64,000 after buying an additional 335 shares during the period. Finally, Blue Trust Inc. increased its position in shares of DexCom by 101.9% during the third quarter. Blue Trust Inc. now owns 1,779 shares of the medical device company’s stock worth $119,000 after acquiring an additional 898 shares in the last quarter. 97.75% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

DXCM has been the topic of several research reports. Oppenheimer cut their price objective on shares of DexCom from $115.00 to $105.00 and set an “outperform” rating on the stock in a research report on Friday, October 25th. JPMorgan Chase & Co. raised their price target on shares of DexCom from $75.00 to $85.00 and gave the stock a “neutral” rating in a research note on Friday, October 25th. Wells Fargo & Company boosted their price objective on shares of DexCom from $90.00 to $94.00 and gave the stock an “overweight” rating in a research report on Wednesday, December 11th. Royal Bank of Canada reduced their target price on shares of DexCom from $120.00 to $115.00 and set an “outperform” rating for the company in a report on Friday, October 25th. Finally, Raymond James lowered their price target on shares of DexCom from $115.00 to $99.00 and set a “strong-buy” rating on the stock in a research note on Friday, October 25th. Seven investment analysts have rated the stock with a hold rating, eleven have issued a buy rating and one has given a strong buy rating to the stock. According to MarketBeat, DexCom presently has a consensus rating of “Moderate Buy” and an average target price of $98.00.

DexCom Trading Up 0.9 %

Shares of DXCM stock opened at $80.09 on Friday. DexCom, Inc. has a 12-month low of $62.34 and a 12-month high of $142.00. The company has a market capitalization of $31.28 billion, a PE ratio of 47.96, a price-to-earnings-growth ratio of 2.46 and a beta of 1.12. The firm has a 50 day moving average price of $76.78 and a two-hundred day moving average price of $79.52. The company has a quick ratio of 2.12, a current ratio of 2.46 and a debt-to-equity ratio of 1.23.

Insider Buying and Selling at DexCom

In related news, EVP Sadie Stern sold 4,259 shares of the business’s stock in a transaction that occurred on Wednesday, November 20th. The stock was sold at an average price of $74.73, for a total value of $318,275.07. Following the completion of the sale, the executive vice president now directly owns 71,192 shares in the company, valued at approximately $5,320,178.16. The trade was a 5.64 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through this link. Insiders own 0.30% of the company’s stock.

DexCom Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.